Accessibility Menu
Vyome logo

Vyome(NASDAQ) HIND

Market Cap$15.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-84%
5 Year-100%
1 Year-86%
1 Month-4%
$2.27
+4.13%
+0.09Today
After hours$2.29+$0.02 (+0.88%)
Vyome last closing stock price
MetricPriceDate
Last closeUSD 2.182026-08-14
Vyome stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.93%USD 2.162026-08-07
1 month-3.96%USD 2.272026-07-15
3 month+15.34%USD 1.892026-05-15
Year to date-36.63%USD 3.442025-12-31
1 year-86.1%USD 15.682025-08-14
3 year-99.97%USD 6,902.002023-08-15
5 year-100%USD 922,200.002021-08-13
Since inception-84.43%USD 14.002025-08-15

Vyome Financials at a Glance

Market Cap

$15.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$129.72K

Net Income (TTM)

-$11.31M

EPS (TTM)

-$3.51

P/E Ratio

-0.62

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$2.27

Volume

14,413.631

Open

$2.13

Previous Close

$2.27

Daily Range

$2.13 - $2.30

52-Week Range

$1.75 - $12.87

Estimated Earnings Date

Nov 13, 2026

HIND News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vyome

Vyome develops medicines for rare immune and inflammatory diseases. Its products help people with severe skin and eye conditions. Vyome’s treatments aim to improve quality of life for patients with limited options.

Vyome’s Toolbox: What’s on Offer?

  • Biotechnology pipeline: New topical gels and eye drops for rare skin and eye diseases; 0% of 2025 revenue.
  • Pharmaceutical products: Reformulated antifungal creams and shampoos for skin and scalp conditions; 100% of 2025 revenue.
  • Licensing and royalties: Income from licensing products to Sun Pharma in India; 100% of 2025 revenue.

Growth Moves: Vyome’s Expansion Playbook

  • Completed merger with ReShape Lifesciences in August 2025, expanding pipeline and resources.
  • Entered licensing and marketing partnership with Sun Pharma for antifungal products in India (ongoing since before 2024).
  • Discontinued direct sales of dandruff products in December 2024, shifting to a royalty and service fee model.
  • Initiated plans for Phase 3 clinical trial of VT-1953 for rare cancer wounds, targeting 2026.

What Makes Vyome Stand Out?

Vyome repurposes existing drug ingredients for new uses, aiming to reduce development costs and timelines. The company leverages operations in both the US and India for cost efficiency and access to clinical trial participants. Its business model relies on partnerships for commercialization, rather than direct sales.

Five Things You Need to Know

  • Revenue was $2 million in Q4 2025, down 88.4% from Q4 2024.
  • Net loss was $2 million in Q4 2025, a 214.7% decrease from Q4 2024.
  • All 2025 revenue came from Sun Pharma licensing and royalties in India.
  • Cash flow from operations was negative $6 million in Q4 2025, down 738% year-over-year.
  • Vyome had 18 employees and $4.98 million in cash at year-end 2025.

Bottom Line

Vyome has shifted from legacy antifungal products to developing new treatments for rare diseases. The company’s future depends on advancing its pipeline and managing reliance on a single partner for revenue.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

18

CEO

Venkateswarlu Nelabhotla, MBA

Website

www.vyometx.com

Headquarters

Cambridge, MA 02138, US

HIND Financials

Key Financial Metrics (TTM)

Gross Margin

46.50%

Operating Margin

-3250.25%

Net Income Margin

-8716.77%

Return on Equity

-254.62%

Return on Capital

-111.07%

Return on Assets

-123.23%

Earnings Yield

-1.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.02M

Volume

14.41K

Avg. Volume

17.38K

Financials (TTM)

Gross Profit

$60.32K

Operating Income

-$4.22M

EBITDA

-$11.53M

Operating Cash Flow

-$5.25M

Capital Expenditure

-$1.00

Free Cash Flow

-$5.25M

Cash & ST Invst.

$7.89M

Total Debt

$17.31K

Vyome Performance Analysis

Vyome annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,240,000-17.4%
20232023-12-31USD 8,678,000-22.8%
20242024-12-31USD 256,944-97.0%
20252025-12-31USD 319,71424.4%
Vyome sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-97.2%
Q42025-12-315.6%
Q12026-03-31-13.6%
Q22026-06-30-14.7%
Vyome annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -631,591.70-62.3%
20232023-12-31USD -11,087.74-98.2%
20242024-12-31USD -24.45-99.8%
20252025-12-31USD -4.75-80.6%
Vyome sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-226.9%
Q42025-12-3199.3%
Q12026-03-3119.0%
Q22026-06-3041.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$26.96K

-97.8%

Gross Profit

$11.66K

-98.1%

Gross Margin

43.25%

N/A

Market Cap

$15.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$850.02K

N/A

Employees

18

N/A

Net Income

-$685.56K

+73.9%

EBITDA

-$713.75K

+72.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.89M

+91.3%

Total Debt

$17.31K

-83.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$17.31K

-83.4%

Return on Assets

-1.23%

N/A

Return on Invested Capital

-57.67%

N/A

Free Cash Flow

-$6.68M

-48.7%

Operating Cash Flow

-$6.68M

-48.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMDXInsight Molecular Diagnostics Inc.
$4.27-1.16%
CDXSCodexis, Inc.
$1.59+1.92%
TNXPTonix Pharmaceuticals Holding Corp.
$12.66-0.39%
IPHAInnate Pharma S.A.
$2.26+3.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About HIND

What is the current price of Vyome?

Vyome is trading at $2.27 per share.

What is the 52-week range for Vyome?

Over the past 52 weeks, Vyome has traded between $1.75 and $12.87.

How much debt does Vyome have?

As of the most recent reporting period, Vyome reported total debt of $17.31K.

How much cash does Vyome have on hand?

Vyome reported $7.89M in cash and cash equivalents in its most recent financial results.

What is Vyome’s dividend yield?

Vyome does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services